Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response

TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy

(2018) Sanja Aveic et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-GBM-induced lupus-like nephritis

(2018) Yuxuan Zhen et al.   JOURNAL OF AUTOIMMUNITY

Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy

(2018) Anuja Sathe et al.   PLoS One

Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors

(2018) Emilie Clement et al.   Science Signaling

Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors

(2018) Emilie Clement et al.   Science Signaling

Restraining Akt1 Phosphorylation Attenuates the Repair of Radiation-Induced DNA Double-Strand Breaks and Reduces the Survival of Irradiated Cancer Cells

(2018) Klaudia Szymonowicz et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents

(2018) Nellie K McDaniel et al.   MOLECULAR CANCER THERAPEUTICS

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

(2018) Sandra Misale et al.   CLINICAL CANCER RESEARCH

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

(2018) Maura L Gillison et al.   LANCET

Akt1 Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in a Rad51-Dependent Manner

(2017) Katharina Mueck et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Nuclear insulin-like growth factor 1 receptor phosphorylates proliferating cell nuclear antigen and rescues stalled replication forks after DNA damage

(2017) Ahmed Waraky et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group Trial (E3205)

(2017) Madhur K. Garg et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial

(2017) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Epigenetic regulation of RTK signaling

(2017) Jennifer M Spangle et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Drugging the Cancers Addicted to DNA Repair

(2017) Jac A. Nickoloff et al.   JNCI-Journal of the National Cancer Institute

Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression

(2017) Canan Kasikara et al.   MOLECULAR CANCER RESEARCH

Maximising the potential of AKT inhibitors as anti-cancer treatments

(2017) Jessica S. Brown et al.   PHARMACOLOGY & THERAPEUTICS

New roles for nuclear EGFR in regulating the stability and translation of mRNAs associated with VEGF signaling

(2017) Klaus Dittmann et al.   PLoS One

The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

(2017) Toni M. Brand et al.   Science Signaling

ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells

(2017) Cyril Ronco et al.   MedChemComm

Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo

(2017) Chih-Chia Yu et al.   Oncotarget

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer

(2017) Jian-Zhong Lin et al.   Oncotarget

Drugging the Cancers Addicted to DNA Repair

(2017) Jac A. Nickoloff et al.   JNCI-Journal of the National Cancer Institute

The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

(2017) Toni M. Brand et al.   Science Signaling

Activating Akt1 mutations alter DNA double strand break repair and radiosensitivity

(2017) S. Oeck et al.   Scientific Reports

Effects of different ligands on epidermal growth factor receptor (EGFR) nuclear translocation

(2016) Jerusa A.Q.A. Faria et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer

(2016) E. J. Hill et al.   CLINICAL CANCER RESEARCH

AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers

(2016) Kavitha Balaji et al.   MOLECULAR CANCER RESEARCH

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab

(2016) M. Iida et al.   MOLECULAR CANCER THERAPEUTICS

ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer

(2016) James M. Wilson et al.   RADIOTHERAPY AND ONCOLOGY

Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer

(2016) Mahmoud Toulany et al.   Oncotarget

Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells

(2016) Marina Holler et al.   PLoS One

Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities

(2015) Jun Zhang et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response

(2015) Hong-Jen Lee et al.   CELL RESEARCH

Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models

(2015) D. M. Francis et al.   CLINICAL CANCER RESEARCH

Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors

(2015) S. Sinha et al.   CLINICAL CANCER RESEARCH

AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma

(2015) T. M. Brand et al.   CLINICAL CANCER RESEARCH

Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells

(2015) Raymond Reif et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

(2015) Jeffrey D Bradley et al.   LANCET ONCOLOGY

YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors

(2015) G. C. Stachelek et al.   MOLECULAR CANCER RESEARCH

ATM and ATR as therapeutic targets in cancer

(2015) Anika Maria Weber et al.   PHARMACOLOGY & THERAPEUTICS

Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation

(2015) Mahmoud Toulany et al.   SEMINARS IN CANCER BIOLOGY

Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab

(2015) Mari Iida et al.   NEOPLASIA

Crosstalk between IGF-1R and other Tumor Promoting Pathways

(2014) Changyu Liu et al.   CURRENT PHARMACEUTICAL DESIGN

EGFR Modulates DNA Synthesis and Repair through Tyr Phosphorylation of Histone H4

(2014) Ruey-Hwang Chou et al.   DEVELOPMENTAL CELL

Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition

(2014) Kunal A. Lodhia et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non–Small-Cell Lung Cancer

(2014) Puneeth Iyengar et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522

(2014) K. Kian Ang et al.   JOURNAL OF CLINICAL ONCOLOGY

A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma

(2014) J. L. Clarke et al.   NEURO-ONCOLOGY

Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule

(2014) Sebastian Kuger et al.   Translational Oncology

Silencing of insulin-like growth factor-1 receptor enhances the radiation sensitivity of human esophageal squamous cell carcinoma in vitro and in vivo

(2014) Hui Zhao et al.   World Journal of Surgical Oncology

Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial†

(2013) E. Deutsch et al.   ANNALS OF ONCOLOGY

ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition

(2013) Mahmoud Toulany et al.   CANCER BIOLOGY & THERAPY

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

(2013) J. Casal Rubio et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

(2013) Thomas Crosby et al.   LANCET ONCOLOGY

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination

(2013) M M Chitnis et al.   ONCOGENE

Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer

(2013) Jeroen Buijsen et al.   RADIOTHERAPY AND ONCOLOGY

Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells

(2013) Mohammad Saki et al.   RADIOTHERAPY AND ONCOLOGY

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

DNA Double-Strand Break Repair as Determinant of Cellular Radiosensitivity to Killing and Target in Radiation Therapy

(2013) Emil Mladenov et al.   Frontiers in Oncology

Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation

(2012) S. Huang et al.   CANCER RESEARCH

Molecular alterations in AKT and its protein activation in human lung carcinomas

(2012) Yoh Dobashi et al.   HUMAN PATHOLOGY

A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response

(2012) Ramesh Rengan et al.   Journal of Thoracic Oncology

Akt Promotes Post-Irradiation Survival of Human Tumor Cells through Initiation, Progression, and Termination of DNA-PKcs-Dependent DNA Double-Strand Break Repair

(2012) M. Toulany et al.   MOLECULAR CANCER RESEARCH

Inhibition of Non-Homologous End Joining Repair Impairs Pancreatic Cancer Growth and Enhances Radiation Response

(2012) Ying-Hua Li et al.   PLoS One

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

(2012) Somaira Nowsheen et al.   PLoS One

Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks

(2012) Benjamin W. Turney et al.   RADIOTHERAPY AND ONCOLOGY

PI3K-PKB/Akt Pathway

(2012) B. A. Hemmings et al.   Cold Spring Harbor Perspectives in Biology

Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck

(2011) John D. Hainsworth et al.   CANCER JOURNAL

MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks

(2011) Michael Fraser et al.   CELL CYCLE

Prospective Study of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Concurrent With Individualized Radiotherapy for Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

(2011) Jing Wang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

K-RAS(V12) Induces Autocrine Production of EGFR Ligands and Mediates Radioresistance Through EGFR-Dependent Akt Signaling and Activation of DNA-PKcs

(2011) Minjmaa Minjgee et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Insulin-Like Growth Factor–Type 1 Receptor Inhibitor NVP-AEW541 Enhances Radiosensitivity of PTEN Wild-Type but Not PTEN-Deficient Human Prostate Cancer Cells

(2011) Sofie F. Isebaert et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience

(2011) Chih-Chia Chang et al.   LUNG CANCER

In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status

(2011) Laura Myllynen et al.   RADIOTHERAPY AND ONCOLOGY

Function of erbB receptors and DNA-PKcs on phosphorylation of cytoplasmic and nuclear Akt at S473 induced by erbB1 ligand and ionizing radiation

(2011) Mahmoud Toulany et al.   RADIOTHERAPY AND ONCOLOGY

The role of homologous recombination in radiation-induced double-strand break repair

(2011) Penny A. Jeggo et al.   RADIOTHERAPY AND ONCOLOGY

Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors

(2010) Hui Song et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells

(2010) Sarah E. Golding et al.   CANCER BIOLOGY & THERAPY

R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

(2010) S. J. Holland et al.   CANCER RESEARCH

DNA mismatch repair and the DNA damage response to ionizing radiation: Making sense of apparently conflicting data

(2010) Lynn M. Martin et al.   CANCER TREATMENT REVIEWS

Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung

(2010) Donatella Malanga et al.   CELL CYCLE

Phosphoinositide-3-Kinase Inhibition Enhances Radiosensitization of Cervical Cancer In Vivo

(2010) Yi Liu et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Targeting Epidermal Growth Factor Receptor-Associated Signaling Pathways in Non-Small Cell Lung Cancer Cells: Implication in Radiation Response

(2010) E. J. Choi et al.   MOLECULAR CANCER RESEARCH

PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541

(2010) Daniel Hägerstrand et al.   NEURO-ONCOLOGY

PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation

(2010) R Deng et al.   ONCOGENE

Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy

(2010) G. Pueyo et al.   ONCOLOGIST

ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway

(2010) Mahmoud Toulany et al.   RADIOTHERAPY AND ONCOLOGY

DNA Repair Targeting and Radiotherapy: A Focus on the Therapeutic Ratio

(2010) John Thoms et al.   SEMINARS IN RADIATION ONCOLOGY

Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non-Small Cell Lung Cancer Cells

(2009) T. Iwasa et al.   CLINICAL CANCER RESEARCH

Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors

(2009) S.-C. Wang et al.   CLINICAL CANCER RESEARCH

AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma

(2009) Yoram Cohen et al.   GYNECOLOGIC ONCOLOGY

DNA-dependent Protein Kinase-mediated Phosphorylation of Protein Kinase B Requires a Specific Recognition Sequence in the C-terminal Hydrophobic Motif

(2009) Jongsun Park et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MRE11-RAD50-NBS1 Complex Dictates DNA Repair Independent of H2AX

(2009) Jingsong Yuan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K

(2009) J M Askham et al.   ONCOGENE

Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells

(2009) Hui-Fang Li et al.   Radiation Oncology

Backup pathways of NHEJ in cells of higher eukaryotes: Cell cycle dependence

(2009) George Iliakis   RADIOTHERAPY AND ONCOLOGY

Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells

(2008) L. Li et al.   CANCER RESEARCH

Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer

(2008) Thomas B. Brunner et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer

(2008) Johan Bussink et al.   LANCET ONCOLOGY

Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair

(2008) M. Toulany et al.   MOLECULAR CANCER THERAPEUTICS

PKBα/Akt1 Acts Downstream of DNA-PK in the DNA Double-Strand Break Response and Promotes Survival

(2008) Lana Bozulic et al.   MOLECULAR CELL

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

AKT1 E17K in human solid tumours

(2008) F E Bleeker et al.   ONCOGENE

Clinical Significance of Insulin-Like Growth Factor Type 1 Receptor and Epidermal Growth Factor Receptor in Patients with Advanced Gastric Cancer

(2008) Junichi Matsubara et al.   ONCOLOGY